Search Result

Results for "

Dargistotug

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Fungal (2) MEK (1) Src (1) Transmembrane Glycoprotein (3)
By Research Areas:	Cancer (5) Infection (2) Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P11446

AE105	Transmembrane Glycoprotein	Cancer
AE105 is a 9-mer peptide probe targeting the urokinase-type plasminogen activator receptor (uPAR). AE105 binds tightly to the uPA-binding cavity of uPAR. AE105 can be used for the study of cancer .

HY-146127A

Grb2 SH2 domain inhibitor 1 TFA	Src	Others
Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.

HY-146127

Grb2 SH2 domain inhibitor 1	MEK	Cancer
Grb2 SH2 domain inhibitor 1 is an inhibitor of the Grb2 SH2 domain with an IC₅₀ of 0.40 μM. Grb2 SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2 SH2 domain inhibitor 1 downregulates the expression level of p-MEK. Grb2 SH2 domain inhibitor 1 can be used in the research of breast cancer .

HY-P10304C

*Cyclo(Pro-dArg)*	Fungal	Infection
Cyclo(Pro-dArg) is an inhibitor of chitinase. Cyclo(Pro-dArg) inhibits the cell separation of Saccharomyces cerevisiae but does not affect its growth. Cyclo(Pro-dArg) inhibits the transition of Candida albicans from yeast to filamentous morphology.

HY-P990031

*Dargistotug* M-6223	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .

HY-P11446A

AE105 TFA	Transmembrane Glycoprotein	Cancer
AE105 TFA is a 9-mer peptide probe targeting the urokinase-type plasminogen activator receptor (uPAR). AE105 TFA binds tightly to the uPA-binding cavity of uPAR. AE105 TFA can be used for the study of cancer .

HY-P10304D

*Cyclo(Pro-dArg) acetate*	Fungal	Infection
Cyclo(Pro-dArg) acetate is a chitinase inhibitor. Cyclo(Pro-dArg) acetate inhibits the cell separation of Saccharomyces cerevisiae but does not affect its growth. Cyclo(Pro-dArg) acetate inhibits the transition of Candida albicans from yeast to filamentous morphology .

HY-P11807

DArg-DLys-DTyr-DTyr-Gly-DTrp	ADC Linker	Cancer
DArg-DLys-DTyr-DTyr-Gly-DTrp is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Target	Research Area

HY-P11446

AE105	Transmembrane Glycoprotein	Cancer
AE105 is a 9-mer peptide probe targeting the urokinase-type plasminogen activator receptor (uPAR). AE105 binds tightly to the uPA-binding cavity of uPAR. AE105 can be used for the study of cancer .

HY-146127A

Grb2 SH2 domain inhibitor 1 TFA	Src	Others
Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.

HY-146127

Grb2 SH2 domain inhibitor 1	MEK	Cancer
Grb2 SH2 domain inhibitor 1 is an inhibitor of the Grb2 SH2 domain with an IC₅₀ of 0.40 μM. Grb2 SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2 SH2 domain inhibitor 1 downregulates the expression level of p-MEK. Grb2 SH2 domain inhibitor 1 can be used in the research of breast cancer .

HY-P10304C

*Cyclo(Pro-dArg)*	Fungal	Infection
Cyclo(Pro-dArg) is an inhibitor of chitinase. Cyclo(Pro-dArg) inhibits the cell separation of Saccharomyces cerevisiae but does not affect its growth. Cyclo(Pro-dArg) inhibits the transition of Candida albicans from yeast to filamentous morphology.

HY-P11446A

AE105 TFA	Transmembrane Glycoprotein	Cancer
AE105 TFA is a 9-mer peptide probe targeting the urokinase-type plasminogen activator receptor (uPAR). AE105 TFA binds tightly to the uPA-binding cavity of uPAR. AE105 TFA can be used for the study of cancer .

HY-P10304D

*Cyclo(Pro-dArg) acetate*	Fungal	Infection
Cyclo(Pro-dArg) acetate is a chitinase inhibitor. Cyclo(Pro-dArg) acetate inhibits the cell separation of Saccharomyces cerevisiae but does not affect its growth. Cyclo(Pro-dArg) acetate inhibits the transition of Candida albicans from yeast to filamentous morphology .

HY-P11807

DArg-DLys-DTyr-DTyr-Gly-DTrp	ADC Linker	Cancer
DArg-DLys-DTyr-DTyr-Gly-DTrp is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990031

*Dargistotug* M-6223	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.